Health Risks of Sarcopenic Obesity in Overweight Children and Adolescents: Data from the CHILT III Programme (Cologne)

Publikationen: Beitrag in FachzeitschriftZeitschriftenaufsätzeForschungBegutachtung

Standard

Health Risks of Sarcopenic Obesity in Overweight Children and Adolescents : Data from the CHILT III Programme (Cologne). / Sack, Carolin; Ferrari, Nina; Friesen, David et al.

in: Journal of Clinical Medicine, Jahrgang 11, Nr. 1, 05.01.2022.

Publikationen: Beitrag in FachzeitschriftZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{aa3f91a71d82472ca480d6140478ce5f,
title = "Health Risks of Sarcopenic Obesity in Overweight Children and Adolescents: Data from the CHILT III Programme (Cologne)",
abstract = "Sarcopenic obesity is increasingly found in youth, but its health consequences remain unclear. Therefore, we studied the prevalence of sarcopenia and its association with cardiometabolic risk factors as well as muscular and cardiorespiratory fitness using data from the German Children's Health InterventionaL Trial (CHILT III) programme. In addition to anthropometric data and blood pressure, muscle and fat mass were determined with bioelectrical impedance analysis. Sarcopenia was classified via muscle-to-fat ratio. A fasting blood sample was taken, muscular fitness was determined using the standing long jump, and cardiorespiratory fitness was determined using bicycle ergometry. Of the 119 obese participants included in the analysis (47.1% female, mean age 12.2 years), 83 (69.7%) had sarcopenia. Affected individuals had higher gamma-glutamyl transferase, higher glutamate pyruvate transaminase, higher high-sensitivity C-reactive protein, higher diastolic blood pressure, and lower muscular and cardiorespiratory fitness (each p < 0.05) compared to participants who were 'only' obese. No differences were found in other parameters. In our study, sarcopenic obesity was associated with various disorders in children and adolescents. However, the clinical value must be tested with larger samples and reference populations to develop a unique definition and appropriate methods in terms of identification but also related preventive or therapeutic approaches.",
keywords = "Juvenile obesity, Muscle-to-fat ratio, Sarcopenia, Sarcopenic obesity",
author = "Carolin Sack and Nina Ferrari and David Friesen and Fabiola Haas and Marlen Klaudius and Lisa Schmidt and Gabriel Torbahn and Hagen Wulff and Christine Joisten",
year = "2022",
month = jan,
day = "5",
doi = "10.3390/jcm11010277",
language = "English",
volume = "11",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI AG",
number = "1",

}

RIS

TY - JOUR

T1 - Health Risks of Sarcopenic Obesity in Overweight Children and Adolescents

T2 - Data from the CHILT III Programme (Cologne)

AU - Sack, Carolin

AU - Ferrari, Nina

AU - Friesen, David

AU - Haas, Fabiola

AU - Klaudius, Marlen

AU - Schmidt, Lisa

AU - Torbahn, Gabriel

AU - Wulff, Hagen

AU - Joisten, Christine

PY - 2022/1/5

Y1 - 2022/1/5

N2 - Sarcopenic obesity is increasingly found in youth, but its health consequences remain unclear. Therefore, we studied the prevalence of sarcopenia and its association with cardiometabolic risk factors as well as muscular and cardiorespiratory fitness using data from the German Children's Health InterventionaL Trial (CHILT III) programme. In addition to anthropometric data and blood pressure, muscle and fat mass were determined with bioelectrical impedance analysis. Sarcopenia was classified via muscle-to-fat ratio. A fasting blood sample was taken, muscular fitness was determined using the standing long jump, and cardiorespiratory fitness was determined using bicycle ergometry. Of the 119 obese participants included in the analysis (47.1% female, mean age 12.2 years), 83 (69.7%) had sarcopenia. Affected individuals had higher gamma-glutamyl transferase, higher glutamate pyruvate transaminase, higher high-sensitivity C-reactive protein, higher diastolic blood pressure, and lower muscular and cardiorespiratory fitness (each p < 0.05) compared to participants who were 'only' obese. No differences were found in other parameters. In our study, sarcopenic obesity was associated with various disorders in children and adolescents. However, the clinical value must be tested with larger samples and reference populations to develop a unique definition and appropriate methods in terms of identification but also related preventive or therapeutic approaches.

AB - Sarcopenic obesity is increasingly found in youth, but its health consequences remain unclear. Therefore, we studied the prevalence of sarcopenia and its association with cardiometabolic risk factors as well as muscular and cardiorespiratory fitness using data from the German Children's Health InterventionaL Trial (CHILT III) programme. In addition to anthropometric data and blood pressure, muscle and fat mass were determined with bioelectrical impedance analysis. Sarcopenia was classified via muscle-to-fat ratio. A fasting blood sample was taken, muscular fitness was determined using the standing long jump, and cardiorespiratory fitness was determined using bicycle ergometry. Of the 119 obese participants included in the analysis (47.1% female, mean age 12.2 years), 83 (69.7%) had sarcopenia. Affected individuals had higher gamma-glutamyl transferase, higher glutamate pyruvate transaminase, higher high-sensitivity C-reactive protein, higher diastolic blood pressure, and lower muscular and cardiorespiratory fitness (each p < 0.05) compared to participants who were 'only' obese. No differences were found in other parameters. In our study, sarcopenic obesity was associated with various disorders in children and adolescents. However, the clinical value must be tested with larger samples and reference populations to develop a unique definition and appropriate methods in terms of identification but also related preventive or therapeutic approaches.

KW - Juvenile obesity

KW - Muscle-to-fat ratio

KW - Sarcopenia

KW - Sarcopenic obesity

UR - https://www.mendeley.com/catalogue/9cf49fef-67e5-3143-8336-7e9589a93612/

U2 - 10.3390/jcm11010277

DO - 10.3390/jcm11010277

M3 - Journal articles

C2 - 35012017

VL - 11

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 1

ER -

ID: 6578872